Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor
Conditions
Interventions
Intervention 1: Intervention Group 1:A total of 25 participants in this group will receive bromelain, taking two 200 mg bromelain capsules daily (one with breakfast and one with lunch) for 12 weeks. T
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Rheumatoid Arthritis Based on American College of Rheumatology (ACR) Criteria(If there are at least four criteria for six weeks of the criteria 1- Morning dryness for at least one hour in three joints or more 2- Arthritis of three joint areas or more 3- Arthritis of the hand joints 4- Symmetric arthritis 5- Rheumatoid nodules 6- Positive rheumatoid factor 7- Typical radiographic changes in the wrist and hand) The duration of the disease should be at least two years. The patient expresses his / her consent to participate in the study
Exclusion criteria
Exclusion criteria: Taking supplements (omega 3, antioxidants, etc.) in the last two months Having any of the diseases of diabetes, hypertension, thyroid disorder and kidney failure and Liver dysfunction Changes in the amount of medication taken in the past month Pregnancy and lactation Taking contraceptives People who are allergic to pineapple, carrots, and fennel. People who take anticoagulant medications. Substance abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumour necrosis factor- a (TNF-a). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Total antioxidant capacity (TAC). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Chromatography.;Erythrocyte sedimentation rate (ESR). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Westergren method.;Malondialdehyde (MDA). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Chromatography.;Interferon gamma (IFN-?). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Interleukin-17 (IL-17). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;C-reactive protein (CRP). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Immunoturbidometric method.;Disease activity score. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Formula DAS28.;Illness severity. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Physician global assessment.;Pain. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Visual analogue scale.;Morning stiffness. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: How long (minutes) it takes for the joint dryness to go away.;Number of painful joints. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Doctor's examination.;Tender joint counts (TJC). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Doctor's examination.;Swollen joint count. Timepoint: | — |
Secondary
| Measure | Time frame |
|---|---|
| Dosage of drugs. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaheed Aryaeian
Iran University of Medical Sciences
Outcome results
None listed